COVID-19 and diabetes: What do we know so far?

Area of Science:

• Medical Science
• Immunology
• Endocrinology

Background:

• Diabetes and COVID-19 (Coronavirus disease 2019) co-occurrence presents significant clinical challenges.
• Diabetic patients exhibit higher rates of severe symptoms, rapid disease progression, and mortality compared to non-diabetic individuals.
• Underlying pro-inflammatory states and circulatory complications in diabetes exacerbate COVID-19 severity.

Purpose of the Study:

• To elucidate the mechanisms linking diabetes comorbidities to adverse outcomes in COVID-19 patients.
• To review the specific pathological conditions in diabetes that contribute to poor prognosis when infected with SARS-CoV-2.

Main Methods:

• This study is a comprehensive literature review.
• It synthesizes existing research on the interplay between diabetes and COVID-19 pathogenesis.
• Focuses on metabolic and inflammatory pathways.

Main Results:

• Hyperglycemia in diabetic patients worsens the pro-inflammatory response to COVID-19.
• Insulin resistance and impaired pancreatic function contribute to disease severity.
• Advanced glycation end products (AGEs) formation is linked to poor clinical outcomes.
• Diabetic circulatory issues are compounded by COVID-19, increasing clotting risks.

Conclusions:

• Diabetic comorbidities like hyperglycemia and insulin resistance critically impair COVID-19 outcomes.
• Understanding these mechanisms is essential for developing targeted management strategies for diabetic patients with COVID-19.
• Further research into AGEs and circulatory complications is warranted.